Department of Ophthalmology, Virgen Macarena University Hospital, Seville, Spain.
Retics OftaRed, Institute of Health Carlos III, Madrid, Spain.
Int Ophthalmol. 2024 Sep 6;44(1):371. doi: 10.1007/s10792-024-03282-8.
To describe our experience over 6 years using a new high-density polyethylene-based spherical integrated porous orbital implants (Oculfit).
This is an observational retrospective case series study analyzing all cases requiring Oculfit implants between February 2015 and September 2021. Clinical information regarding the population included, the characteristics of the implant, and the outcomes and complications during the follow-up were noted. The success of the implant was defined according to anatomical and functional parameters.
The study analyzed 90 cases of anophthalmic patients. The main causes for enucleation or evisceration were ocular decompensations (36.7%) and neoplasms (27.8% uveal melanoma and 7.8% retinoblastoma). Anatomical success was identified in 63 (70.0%) cases, functional success in 79 (87.8%) and complete success (anatomical + functional) in 61 (67.7%) cases. Factors associated with the functional success were age and exposure of the primary orbital implant. Complications appeared in 11 (12.2%) cases, which were completely resolved without sequelae in 4 (4.4%). Orbital explant was required in 5 (5.6%) cases.
In our experience, Oculfit can be considered a useful alternative among the currently available options for orbital implants and has a good efficacy/safety profile.
描述我们在过去 6 年中使用新型高密度聚乙烯球形一体化多孔眼眶植入物(Oculfit)的经验。
这是一项回顾性观察性病例系列研究,分析了 2015 年 2 月至 2021 年 9 月期间所有需要 Oculfit 植入物的病例。记录了纳入人群的临床信息,包括植入物的特征以及随访期间的结果和并发症。根据解剖学和功能参数定义植入物的成功。
研究分析了 90 例无眼患者。眼球摘除或眼内容剜除的主要原因是眼组织失代偿(36.7%)和肿瘤(27.8%葡萄膜黑色素瘤和 7.8%视网膜母细胞瘤)。63 例(70.0%)病例解剖成功,79 例(87.8%)功能成功,61 例(67.7%)完全成功(解剖+功能)。与功能成功相关的因素是年龄和原发性眼眶植入物的暴露程度。11 例(12.2%)出现并发症,其中 4 例(4.4%)完全解决且无后遗症。5 例(5.6%)需要取出眼眶植入物。
根据我们的经验,Oculfit 可被视为目前可用的眼眶植入物替代方案之一,具有良好的疗效/安全性。